- Patient enrollment is complete in Nymox Pharmaceuticals' (NYMX -0.4%) second re-injection Phase 3 clinical trial evaluating the safety and efficacy on NX-1207 as a treatment of enlarged prostate or benign prostatic hyperplasia (BPH). In the first re-injection study, patients demonstrated a mean symptomatic improvement in the AUA BPH Symptom Score of 7.6 points.
- NX-1207 is administered by injection directly into the prostate gland. It is currently being assessed in five Phase 3 trials and one Phase 2 trial.
Enrollment complete in second BPH Phase 3 trial
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Benzinga.com (Dec 18, 2014)
at MarketWatch.com (Dec 17, 2010)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs